Merial Re-Launches HEARTGARD® (ivermectin) Tablets for Dogs

Dogs with food ingredient allergies now have an alternative to help prevent heartworm disease

Duluth, Ga. – July 16, 2014 – Merial today announced the re-launch of its HEARTGARD® (ivermectin) Tablets. Dogs with food allergies now have a monthly heartworm preventive that does not include any food ingredients that may trigger an allergic reaction.

From the makers of HEARTGARD® Plus (ivermectin/pyrantel), the number one veterinary-recommended heartworm disease preventive, HEARTGARD Tablets help protect against heartworms that can lead to serious illness in dogs. Merial re-introduced these tablets to ensure that every dog has an option for heartworm disease prevention.

"Many dogs suffer from food allergies and most oral heartworm preventives have meat components in their formulation," saidDr. Michael Murray, Technical Marketing Director of U.S. Pets Parasiticides at Merial.[i] "Merial is committed to providing dogs with food allergies an alternative that delivers the same heartworm disease prevention found in HEARTGARD Plus (ivermectin/pyrantel), which is a real beef chewable."

HEARTGARD Tablets are now available through veterinary practices and are backed by the Plus Customer Satisfaction Guarantee, Merial's commitment to proven protection against heartworm disease.

"It is critically important that pet owners maintain year-round heartworm disease prevention every 30 days," added Dr. Murray. "For dogs with special dietary requirements, veterinarians can provide the heartworm protection these pets need with HEARTGARD Tablets."  

To learn more about HEARTGARD products and availability, visit http://www.heartgard.com.

###

 

Important Safety Information: 
HEARTGARD® Tablets and HEARTGARD® Plus are well tolerated. All dogs should be tested for heartworm infection before starting a preventive program. Following the use of HEARTGARD Tablets and HEARTGARD Plus, digestive and neurological side effects have rarely been reported. For complete prescribing information on HEARTGARD Tablets, please visithttp://www.heartgard.com/SiteCollectionDocuments/HEARTGARD-Tablets.pdf. For complete prescribing information on HEARTGARD Plus, please visit http://www.heartgard.com/SiteCollectionDocuments/HEARTGARD-Plus-for-Dogs.pdf.

Indications: 
HEARTGARD® is for use in dogs to prevent canine heartworm disease. HEARTGARD prevents heartworm disease by eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) for a month (30 days) after infection.

HEARTGARD® Plus is for use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) for a month (30 days) after infection and for the treatment and control of ascarids (Toxocaracanis, Toxascaris leonina) and hookworms (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense).

About Merial
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 6,200 people and operates in more than 150 countries worldwide with close to $2 billion of sales in 2013.

Merial is a Sanofi company.

For more information, please see www.merial.com.

 

®HEARTGARD is a registered trademark of Merial. ©2014 Merial Limited, Duluth, GA. All rights reserved. HGD14TRTABLETRELEASE (07/2014)

©2014 Merial Limited, Duluth, GA. All rights reserved.

 

.....

Max Davis | Edelman

Account Executive

1075 Peachtree Street NE, Suite 3100 | Atlanta, GA 30309

Direct: 404-832-6350 | Mobile: 404-664-6262

[email protected] l www.edelman.com

 

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…